European Healthtech startup funding raised during H1 2014.
In H1 2014, 68 European Healthtech companies raised a combined €389M across 70 funding rounds, down 7.1% versus H1 2013. Switzerland led by capital raised, and Imprimatur Capital was the most active investor. Data as of 7 Aug 2026.
| Company | Stage | Date | Amount |
|---|---|---|---|
| NovImmune | Series D+ | Feb 2014 | €49M |
| Wilson Therapeutics | Other | Apr 2014 | €36M |
| uTest_Vamsi | Series D+ | Jan 2014 | €31M |
| Kymab | Series B | May 2014 |
1 exit.
| €29M |
| CRISPR Therapeutics | Series A | Apr 2014 | €23M |
| Voluntis | Series D+ | Apr 2014 | €21M |
| InDex Pharmaceuticals | Other | Feb 2014 | €18M |
| AC Immune | Series D+ | Jan 2014 | €18M |
| Sequana Medical | Series C | Apr 2014 | €17M |
| Bima | Series B | Apr 2014 | €16M |
| Lifeline Ventures Oy | Other | Apr 2014 | €15M |
| OrCam | Growth/Late | Mar 2014 | €11M |
| Enterome | Other | May 2014 | €10M |
| Nyxoah | Series A | May 2014 | €8.0M |
| OxThera | Other | Apr 2014 | €7.7M |
